Subscribe To
FATE / Why Is Fate Therapeutics (FATE) Stock Down 62% Today?
FATE News
By GlobeNewsWire
October 25, 2023
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results
SAN DIEGO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage more_horizontal
By Zacks Investment Research
September 7, 2023
Why Is Fate Therapeutics (FATE) Down 23.5% Since Last Earnings Report?
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? more_horizontal
By GlobeNewsWire
August 31, 2023
Fate Therapeutics to Present at Upcoming September Investor Conferences
SAN DIEGO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage b more_horizontal
By Zacks Investment Research
August 8, 2023
Fate Therapeutics (FATE) Reports Q2 Loss, Lags Revenue Estimates
Fate Therapeutics (FATE) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to lo more_horizontal
By The Motley Fool
June 16, 2023
Why Shares of Fate Therapeutics Soared This Week
Fate Therapeutics is a clinical-stage biotech. The company focuses on cell-derived oncology and immunology therapies. more_horizontal
By Seeking Alpha
May 23, 2023
Fate Therapeutics: The Future Remains Cloudy
Shares of off-the-shelf cell therapy concern Fate Therapeutics, Inc. have cratered 95% since reaching an all-time high in January 2021, punctuated by more_horizontal
By Zacks Investment Research
May 3, 2023
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
Fate Therapeutics (FATE) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to lo more_horizontal
By Zacks Investment Research
May 3, 2023
Fate Therapeutics (FATE) Upgraded to Buy: Here's What You Should Know
Fate Therapeutics (FATE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might dr more_horizontal